Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 4, 2008, Pages 805-809

  Alastruey Izquierdo, Ana ^a   Cuenca Estrella, Manuel ^a   Monzón, Araceli ^a   Mellado, Emilia ^a   Rodríguez Tudela, Juan Luís ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Antifungal resistance; Elongation factor ; Emerging moulds

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ELONGATION FACTOR 1ALPHA; ITRACONAZOLE; POSACONAZOLE; RAVUCONAZOLE; TERBINAFINE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; FUNGAL MORPHOLOGY; FUNGAL STRAIN; FUNGUS ISOLATION; FUSARIUM; FUSARIUM OXYSPORUM; FUSARIUM PROLIFERATUM; FUSARIUM SOLANI; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR MECHANICS; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SPECIES IDENTIFICATION;

ANTIFUNGAL AGENTS; DNA, FUNGAL; DRUG RESISTANCE, FUNGAL; FUSARIUM; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES; PEPTIDE ELONGATION FACTOR 1; PHYLOGENY; SEQUENCE ANALYSIS, DNA;

EID: 41149089785     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn022     Document Type: Article

References (30)

1. Consigny S, Dhedin N, Datry A et al. Successsful voriconazole treatment of disseminated Fusarium infection in an immunocompromised patient. Clin Infect Dis 2003; 37: 311-3.
2. Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: Implications for diagnosis and management. Clin Infect Dis 2002; 35: 909-20.
3. Ferrer C, Alio J, Rodriguez A et al. Endophthalmitis caused by Fusarium proliferatum. J Clin Microbiol 2005; 43: 5372-5.
4. Guarro J, Rubio C, Gene S et al. Case of keratitis caused by an uncommon Fusarium species. J Clin Microbiol 2003; 41: 5823-6.
5. Guarro J, Nucci M, Akiti T et al. Fungemia due to Fusarium sacchari in an immunosuppressed patient. J Clin Microbiol 2000; 38: 419-21.
6. de Hoog G, Guarro J, Tan CS et al. Hyphomycetes. In: De Hoog GS, Guarro J, eds. Atlas of Clinical Fungi. Reus, España and Utrech, The Netherlands: Universitat Rovira i Virgili and Centraalbureau voor Schimmelcultures, 1995; 380-1007.
7. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years experience at a cancer center and implications for management. Blood 1967; 90 999-1008.
8. Kristensen R, Torp, M, Kosiak B et al. Phylogeny and toxigenic potential is correlated in Fusarium species as revealed by partial translation elongation factor 1 α gene sequences. Mycol Res 2005; 109: 173-86.
9. O'Donnell K. Molecular phylogeny of the Mectria haematococca-Fusarium solani species complex. Mycologia 2007; 92: 919-38.
10. Cuenca-Estrella M, Gomez-Lopez A, Mellado E et al. Head-to-head comparison of the activities of currently available anti-fungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006; 50: 917-21.
11. Raad II, Hachem RY, Herbrecht R et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42: 1398-403.
12. Nucci M, Marr KA, Queiroz-Telles F et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004; 38: 1237-42.
13. Denning DW, Radford SA, Oakley KL et al. Correlation between in vitro susceptibility testing to itraconazole and in vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother 1997; 40: 401-14.
14. Dannaoui E, Borel E, Persat F et al. In vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis. EBGA Network. European research group on Biotypes and Genotypes of Aspergillus fumigatus. J Med Microbiol 1999; 48 1087-93.
15. Holden DW. DNA mini prep method for Aspergillus fumigatus (and other filamentous fungi). In: Maresca B, Kobayashi GS, eds. Molecular Biology of Pathogenic Fungi, A Laboratory Manual. New York, NY: Telos Press, 1994; 3-4.
16. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi: Approved Standard M38-A. CLSI, Wayne, PA, USA, 2005.
17. Rodriguez-Tudela JL, Chryssanthou E, Petrikkou E et al. Interlaboratory evaluation of hematocytometer method of inoculum preparation for testing antifungal susceptibilities of filamentous fungi. J Clin Microbiol 2003; 41: 5236-7.
18. Petrikkou E, Rodriguez-Tudela JL, Cuenca-Estrella M et al. Inoculum standardization for antifungal susceptibility testing of filamentous fungi pathogenic for humans. J Clin Microbiol 2001; 39: 1345-7.
19. Aberkane A, Cuenca-Estrella M, Gomez-Lopez A et al. Comparative evaluation of two different methods of inoculum preparation for antifungal susceptibility testing of filamentous fungi. J Antimicrob Chemother 2002; 50: 719-22.
20. Nelson PE, Toussoun TA, Mararas WFO. Fusarium species: An Illustrated Manual for Identification. University Park, PA: The Pennsylvania State University Press, 1983.
21. Pryce TM, Palladino S, Kay ID et al. Rapid identification of fungi by sequencing the ITS1 and ITS2 regions using an automated capillary electrophoresis system. Med Mycol 2003; 41: 369-81.
22. Rodriguez-Tudela JL, Diaz-Guerra TM, Mellado E et al. Susceptibility patterns and molecular identification of Trichosporon species. Antimicrob Agents Chemother 2005; 49: 4026-34.
23. Dornbusch HJ, Buzina W, Summerbell RC et al. Fusarium verticillioides abscess of the nasal septum in an immunosuppressed child: Case report and identification of the morphologically atypical fungal strain. J Clin Microbiol 2005; 43: 1998-2001.
24. O'Donnell K, Cigelnik E. Two divergent intragenomic rDNA ITS2 types within a monophyletic lineage of the fungus Fusarium are non-orthologous. Mol Phylogenet Evol 1997; 7: 103-16.
25. Knutsen AK, Torp M, Holst-Jensen A. Phylogenetic analyses of the Fusarium poae, Fusarium sporotrichioides and Fusarium langsethiae species complex based on partial sequences of the translation elongation factor-1 α gene. Int J Food Microbiol 2004; 95: 287-95.
26. Guarro J, Nucci M, Akiti T et al. Mixed infection caused by two species of Fusarium in a human immunodeficiency virus-positive patient. J Clin Microbiol 2000; 38: 3460-2.
27. Azor M, Gene J, Cano J et al. Universal in vitro antifungal resistance of genetic clades of the Fusarium solani species complex. Antimicrob Agents Chemother 2007; 51: 1500-3.
28. Perfect JR, Marr KA, Walsh TJ et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122-31.
29. Perfect JR. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis 2005; 40 Suppl 6: S401-8.
30. Kontoyiannis DP, Bodey GP, Hanna H et al. Outcome determinants of fusariosis in a tertiary care cancer center the impact of neutrophil recovery. Leuk Lymphoma 2004; 45: 139-44.